{"id":"etec-rctb-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Gastrointestinal symptoms (mild diarrhea, nausea)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses rCTB as a carrier and adjuvant to enhance mucosal and systemic immune responses against ETEC colonization factors and toxins. rCTB binds to GM1 ganglioside receptors on intestinal epithelial cells, promoting uptake and presentation to the immune system. This approach aims to induce protective antibodies and cellular immunity that prevent ETEC infection and toxin-mediated secretory diarrhea.","oneSentence":"This vaccine stimulates immune responses against enterotoxigenic E. coli (ETEC) by presenting the recombinant cholera toxin B subunit (rCTB) as an immunogen to prevent ETEC-induced diarrhea.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:41.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of enterotoxigenic E. coli (ETEC)-induced diarrhea in travelers and military personnel"}]},"trialDetails":[{"nctId":"NCT02556996","phase":"PHASE3","title":"Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"1998-10","conditions":"Diarrhea","enrollment":356},{"nctId":"NCT01109914","phase":"PHASE4","title":"Mucosal Response in Immunocompromised Host","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2010-04","conditions":"Kidney Transplantation, Immunity","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ETEC/rCTB vaccine","genericName":"ETEC/rCTB vaccine","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates immune responses against enterotoxigenic E. coli (ETEC) by presenting the recombinant cholera toxin B subunit (rCTB) as an immunogen to prevent ETEC-induced diarrhea. Used for Prevention of enterotoxigenic E. coli (ETEC)-induced diarrhea in travelers and military personnel.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}